v3.25.4
Segment Reporting - Schedule of reportable segment net income (loss) (Detail) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Segment Reporting Information [Line Items]      
Grant revenue $ 789 $ 0 $ 0
Operating Expenses 94,760 121,315 195,097
Gain on sale of VOWST Business 80,685 5,684 0
Net income (loss) from continuing operations 5,696 (125,771) (190,130)
Net income from discontinued operations, net of tax 0 125,907 76,406
Net income (loss) 5,696 136 (113,724)
Operating Segments [Member]      
Segment Reporting Information [Line Items]      
Grant revenue 789 0 0
R&D personnel-related (including stock-based compensation) 21,553 28,689 65,251
G&A personnel-related (including stock-based compensation) 14,413 22,679 36,069
Professional fees 8,991 9,805 18,784
Facility-related and other 15,752 20,699 22,647
Gain on sale of VOWST Business (80,685) (5,684) 0
Other segment (income) expense [1] (12,191) 13,773 (3,722)
Net income (loss) from continuing operations 5,696 (125,771) (190,130)
Net income from discontinued operations, net of tax [2] 0 125,907 76,406
Net income (loss) 5,696 136 (113,724)
Live Biotherapeutics Platform [Member] | Operating Segments [Member]      
Segment Reporting Information [Line Items]      
Operating Expenses 23,573 29,006 43,342
SER-155 [Member] | Operating Segments [Member]      
Segment Reporting Information [Line Items]      
Operating Expenses $ 3,687 $ 6,804 $ 7,759
[1] Other segment (income) expense includes manufacturing services expenses, research and development expenses on early stage programs, interest income and other (income) expense, net.
[2] See Note 3, Discontinued Operations and TSA, for further details.